Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Agents

Proceedings of the Ninth Annual Symposium on New Drugs & Devices, October 27 & 28, 1988

  • Joel Morganroth
  • E. Neil Moore

Part of the Developments in Cardiovascular Medicine book series (DICM, volume 100)

Table of contents

  1. Front Matter
    Pages i-xvi
  2. Thrombolytic Agents: Clinical Trials Issues

  3. Thrombolytic Agents: Adjunctive Issues

  4. Risk vs. Benefit for Antiarrhythmic Drugs

  5. Hypolipidemic Agents: Clinical & Regulatory Issues

  6. Back Matter
    Pages 279-301

About this book


The Symposium on New Drugs provides a forum for academic investigators, research and development personnel from the pharmaceutical industry and members of the Food and Drug Administration to discuss important clinical research issues. The Ninth Annual symposium on New Drugs addressed the problem of determining the risk versus benefit for use of three important classes of cardiovascular agents: thrombolytic, antiarrhythmic, and hypolipidemic agents. The use of thrombolytic agents has become one of the major advances in clinical intensive cardiologic care in the 1980s. While the lysis of clot(s) obstructing a major coronary artery should reverse or prevent the damage of acute myocardial ischemia and infarction, one must carefully consider the potential risks of such agents in regards to their potential benefits. The time when a thrombolytic agent should be administered to maximize benefit as well as how one defines a dose response relationship using intravenous critical care medicines were discussed as important clinical trial issues. The benefit versus risk data on currently available thrombolytic agents was reviewed and the potential roles for adjunctive agents addressed. Overall strategies regarding post- x thrombolytic care and relationships to sudden cardiac death were also detailed. The panel discussion sections provided a comprehensive view of the current thinking of the various participating groups in this symposium. Sudden cardiac death remains the number one cause of mortality in western industrialized societies.


artery cardiovascular drugs myocardial infarction sudden cardiac death

Editors and affiliations

  • Joel Morganroth
    • 1
  • E. Neil Moore
    • 2
  1. 1.Likoff Cardiovascular Institute of Hahnemann Medical College and HospitalUSA
  2. 2.School of Veterinary MedicineUniversity of PennsylvaniaUSA

Bibliographic information

  • DOI
  • Copyright Information Springer-Verlag US 1989
  • Publisher Name Springer, Boston, MA
  • eBook Packages Springer Book Archive
  • Print ISBN 978-1-4612-8888-6
  • Online ISBN 978-1-4613-1605-3
  • Series Print ISSN 0166-9842
  • Buy this book on publisher's site
Industry Sectors
Health & Hospitals
Internal Medicine & Dermatology